title: The effects of angiotensin II and the oxidative stress mediator 4-hydroxynonenal on human osteoblast-like cell growth: possible relevance to otosclerosis.
abstract: Otosclerosis is a complex disease characterized by an abnormal bone turnover of the otic capsule resulting in conductive hearing loss. Recent findings have shown that angiotensin II (Ang II), a major effector peptide of the renin-angiotensin system, plays an important role in the pathophysiology of otosclerosis, most likely by its proinflammatory effects on the bone cells. Because reactive oxygen species play a role both in inflammation and in the cellular signaling pathway of Ang II, the appearance of protein adducts of the "second messenger of free radicals," the aldehyde 4-hydroxynonenal (HNE), in otosclerotic bone has been analyzed. Immunohistochemical analysis of HNE-modified proteins in tissue samples of the stapedial bones performed on 15 otosclerotic patients and 6 controls revealed regular HNE-protein adducts present in the subperiosteal parts of control bone specimens, whereas irregular areas of a pronounced HNE-protein adduct presence were found within stapedial bone in cases of otosclerosis. To study possible interference by HNE and Ang II in human bone cell proliferation, differentiation, and induction of apoptosis we used an in vitro model of osteoblast-like cells. HNE interacted with Ang II in a dose-dependent manner, both by forming HNE-Ang II adducts, as revealed by immunoblotting, and by modifying its effects on cultured cells. Namely, treatment with 0.1 nM Ang II and 2.5 μM HNE stimulated proliferation, whereas treatment with 10 μM HNE or in combination with Ang II (0.1, 0.5, and 1 nM) decreased cell proliferation. Moreover, 10 μM HNE alone and with Ang II (except if 1 nM Ang II was used) increased cellular differentiation and apoptosis. HNE at 5 μM did not affect differentiation nor significantly change apoptosis. On the other hand, when cells were treated with lower concentrations of HNE and Ang II we observed a decrease in cellular differentiation (combination of 1.0 or 2.5 μM HNE with 0.1 nM Ang II) and decrease in apoptosis (0.1 and 0.5 nM Ang II). Cellular necrosis was increased with 5 and 10 μM HNE if given alone or combined with Ang II, whereas 0.5 nM Ang II and combination of 1 μ M HNE with Ang II (0.1 and 0.5 nM) reduced necrosis. These results indicate that HNE and Ang II might act mutually dependently in the regulation of bone cell growth and in the pathophysiology of otosclerosis.
authors.affiliation: INSERM U-867, Universite Paris-Diderot 7, Paris, France. milan.rudic@yahoo.com
authors.forename: Milan
authors.initials: M
authors.lastname: Rudić
authors.forename: Lidija
authors.initials: L
authors.lastname: Milković
authors.forename: Kamelija
authors.initials: K
authors.lastname: Žarković
authors.forename: Suzana
authors.initials: S
authors.lastname: Borović-Šunjić
authors.forename: Olivier
authors.initials: O
authors.lastname: Sterkers
authors.forename: Georg
authors.initials: G
authors.lastname: Waeg
authors.forename: Evelyne
authors.initials: E
authors.lastname: Ferrary
authors.forename: Alexis
authors.initials: A
authors.lastname: Bozorg Grayeli
authors.forename: Neven
authors.initials: N
authors.lastname: Žarković
mesh_terms: D000447:Aldehydes / Q000378:metabolism* / Q000494:pharmacology; D000804:Angiotensin II / Q000378:metabolism* / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D015853:Cysteine Proteinase Inhibitors / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism*; D010040:Otosclerosis / Q000378:metabolism*; D018384:Oxidative Stress / Q000187:drug effects; D017382:Reactive Oxygen Species / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D000447:Aldehydes; D015853:Cysteine Proteinase Inhibitors; D017382:Reactive Oxygen Species; D000804:Angiotensin II; C027576:4-hydroxy-2-nonenal